PLX-4107 / Plexium - LARVOL DELTA

Discovery of PLX-4107, a selective IKZF2 molecular glue degrader, that modulates suppressive regulatory T cells and demonstrates anti-tumor activity (SITC 2023) - "Co-administration of PLX-4107 and pembrolizumab in xenograft studies resulted in tumor growth inhibition and significant combination benefit. Conclusions PLX-4107 is a novel molecular glue that selectively degrades IKZF2, a transcription factor of suppressive Tregs. PLX-4107 mediated IKZF2 degradation reverses tumor immune evasion by converting Tregs to an effector-like T-cell phenotype, resulting in single agent antitumor activity and the ability to enhance CPI efficacy."

IO biomarker • Oncology • CD4 • CRBN • IFNG • IKZF2 • IL2 • IL2RA